spacer
home > pmps > winter 2002 > editor's letter
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Editor's Letter

The last 12 months have been something of a roller-coaster ride, with some big 'downs' and a few small 'ups'. Just now, we are in a tunnel waiting to find out what lies ahead. Overshadowing the economic climate post September 11th, there have been spectacular crashes like that of Enron Corp., largely due to voodoo accounting practices. Events such as these are a healthy reminder that leveraging earnings to achieve growth also increases risk. So far, the pharmaceutical industry has seemed immune from similar troubles, while the big merger of Pharmacia and Pfizer looks set to create the first mega-pharma company. M&A deals are pharma's attempt to regain shareholder value. However, the news is grim for employment prospects as the industry braces itself for yet more job losses in the wake of post-merger restructuring.


Earlier in the year, analysts predicted improved prospects for manufacturing which could have helped the production sector in pharma and biotech. Outsourced pharmaceutical manufacturing has proved remarkably resilient. It's as well that the industry has the support of a robust infrastructure enabling it to deliver quality products at costs that are lower than that of in-house manufacturing - as long as similar accounting standards are used to compare them. Is this golden scenario about to change to base metal, to match the leaden skies?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Patricia Lobo, Rebecca Cavalôt
spacer
Dr Patricia Lobo
spacer
spacer
spacer
Rebecca Cavalôt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator, with the UK and France close behind

Paris, 19th August 2019: As predicted by the ‘European drug delivery and packaging’ report earlier this year, new data shows innovation in drug delivery is accelerating across Europe – with provisional findings from the Pharmapack Innovation Index (2020) showing that Switzerland has over taken Germany as Europe’s most innovative drug delivery market.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

CPhI Worldwide

5-7 November 2019, Frankfurt, Germany

Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary! Taking place from 5-7 November 2019 in Frankfurt, Germany, the event will bring together more than 45,000 visiting pharma professionals from around the globe and over 2,500 exhibiting pharma companies from every stage of the pharmaceutical supply chain - from ingredients and machinery to outsourcing services, packaging and more!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement